Treatment Science · Investigational Oral Minoxidil
VDPHL01(Veradermics’ Hair Loss Pill):What the Record Shows
VDPHL01 is Veradermics’ investigational extended-release oral minoxidil for pattern hair loss, now in Phase 3 trials. It is not FDA approved and not available outside trials; third-party projections put potential approval in Q4 2027.
Evidence review of Veradermics’ public filings, trial-registry records and patent family · Reviewed by the Anagen Research Team · Last reviewed September 2026
Overview
What is VDPHL01?
VDPHL01 is an investigational oral minoxidil product under development by Veradermics, Inc. Per the company’s filings, it is an extended-release formulation designed to deliver minoxidil’s hair growth benefits while minimizing cardiovascular effects.
Availability
When will VDPHL01 be available?
VDPHL01 is not available to patients today outside clinical trials. Its second Phase 3 trial completed enrollment in early 2026 with results expected in the second half of the year; if development and FDA review succeed, third-party analyses project potential approval in Q4 2027.
- Phase 1 PK studiesReported in the Feb. 2026 prospectusreported
- Study 207, Phase 2Open-label · results August 2026reported
- Study 302, Phase 3Topline April 2026 · 12-month data late 2026reading out
- Studies 304 and 306Readouts late 2026 · first half of 2027pending
- FDA review, potential approvalQ4 2027, per third-party projectionspending
The clinical record
What clinical data does VDPHL01 have so far?
Everything below comes from Veradermics’ own public documents:
| Study | Who got what | Result | When |
|---|---|---|---|
| Phase 1 PK study (unnamed) | Healthy adults; slow-release doses of 5–10 mg vs. a regular 2.5 mg tablet | 8.5 mg slow-release peaked at 8.3 ng/mL. Lower than the plain 2.5 mg tablet’s 13.9 ng/mL. | Date not given; in the Feb. 2026 prospectus |
| Study 109 | 24 women; 4.5 mg slow-release daily for a week, then a 20 mg regular tablet | Slow-release peaked at 6–8 ng/mL vs. 135 for the 20 mg tablet. | Date not given; in the Feb. 2026 prospectus |
| Study 207 (NCT06527365) | 21 men at 8.5 mg and 22 women at 4.5 mg; no placebo group | Men: +47 hairs/cm² at 4 months, per company topline data | Started June 2024; results August 2026 |
| Study 302 (NCT06724614) | 519 men; 8.5 mg once daily, 8.5 mg twice daily, or placebo | Hair counts at month 6: +30.3/cm² (once daily), +33.0 (twice daily), +7.3 (placebo); not yet peer-reviewed | Topline April 2026; 12-month data late 2026 |
| Study 304 (NCT06972264) | Men; 8.5 mg vs. placebo (confirmatory) | No results yet | Expected late 2026 |
| Study 306 (NCT07146022) | 556 women | No results yet | Expected first half of 2027 |
The pharmacokinetics behave the way extended release should. Peaks stay in the single digits with minimal accumulation, and in the company’s own dose-ranging study, plain 2.5 mg immediate-release produced a higher peak (13.9 ng/mL) than the 8.5 mg extended-release prototype (8.3 ng/mL). The efficacy data is promising but early: Study 302’s month-6 topline showed +30.3 hairs/cm² once daily and +33.0 twice daily against +7.3 for placebo. Interestingly, doubling the dose added about three hairs.
None of these studies are peer-reviewed yet, Study 207’s numbers come from an open-label design with no placebo arm, and Studies 304 and 306 haven’t reported complete read outs. And one standard number is still missing from every document: a measured time-to-peak, also known as the TMax. The prospectus also lists treatment-emergent adverse events in the male Phase 2 cohort, including peripheral edema and asymptomatic orthostatic findings, points the company’s topline summaries do not address. Also missing is long-term cardiovascular safety data, the commercial formulation’s composition, and head-to-head comparisons against existing low-dose oral minoxidil practice.
The patent window
What does the “30 to 360 minutes” figure mean?
Veradermics’ patent family describes formulations whose time-to-peak falls between 30 and 360 minutes, half an hour to six hours after dosing, alongside a peak-concentration window of about 0.25 to 20 ng/mL. Whether the commercial VDPHL01 formulation matches that description isn’t publicly known; as noted, no measured time-to-peak has been published.
The window itself is worth understanding, because it describes an early-arriving peak by extended-release standards. A form that peaks at hour one to six front-loads its exposure toward the first half of the day. If a formulation matched that window, its logic would be: rise early, hold the peak inside the claimed concentration range, and accept the earlier decline that comes with an earlier peak.
Release mechanisms
HPMC gels and lipid matrices: two ways to slow a drug down
The patent family’s worked examples use hydroxypropyl methylcellulose, HPMC, the workhorse polymer of extended-release tableting for half a century. An HPMC tablet swells into a gel layer in the stomach, and the drug diffuses out through that gel as it slowly erodes. Release rate is tuned by polymer grade and ratio, and it scales on standard industrial tableting lines.
A lipid matrix, the approach we chose for MINX, disperses the drug in fats that erode and digest gradually, riding the body’s own fat-processing machinery and producing a later, flatter curve. Different release mechanisms sit at different points on the same trade-off: how early the peak arrives, how flat the curve runs, and what it takes to manufacture. Polymer gels are common in industrial extended-release platforms because they scale on standard tableting lines. Lipid systems fit compounded, per-prescription work because they don’t need that infrastructure.
Side by side, on the record
How does VDPHL01 compare to MINX, available today?
Both aim at the same idea: minoxidil’s hair benefit without the immediate-release spike. They differ in nearly everything else. How the lipid-matrix approach works, and our published pilot data, are covered in the MINX introduction and our dose-response analysis. This table sticks to what each side’s public record actually states.
| Compared on | VDPHL01 (per Veradermics’ filings) | MINX (per our published data) |
|---|---|---|
| Status | Investigational; Phase 3 trials ongoing; not FDA approved; not available | Compounded per prescription under 503A; not FDA approved; available by prescription now |
| Delivery | Extended-release; patent examples use HPMC polymer matrix; commercial composition not disclosed | Lipid matrix |
| Doses studied | 4.5 mg (PK, Study 109); 8.5 mg once or twice daily (efficacy, Studies 207/302) | 1.25 mg, 2.5 mg, 5 mg (pilot dosed at 5 mg), 7.5 mg. |
| Measured peak | 6.417–7.735 ng/mL at 4.5 mg (Study 109, 24 healthy women); 8.32 ng/mL at 8.5 mg (exploratory Phase 1) | Modeled ~6.5 ng/mL from a two-person pilot; levels still rising at hour 8 |
| Time-to-peak | Not published; patent family describes a 30–360 minute target | Modeled ~9–10 hours; not directly observed |
| Efficacy evidence | Placebo-controlled topline at 8.5 mg: +30.3 to +33.0 hairs/cm² vs. +7.3 placebo at month 6, per its April 2026 release; full data not yet peer-reviewed | None claimed; no clinical trial; Patient reviews are public online. |
| Availability | Pending remaining readouts and FDA review; potentially late 2027–2028 | Today, by prescription, through 503A compounding |
- 20 mg regular tabletStudy 109, 24 women, after a washout135 ng/mL
- 2.5 mg regular tabletPhase 1 dose-ranging13.9 ng/mL
- 8.5 mg extended-releasePhase 1 dose-ranging, exploratory8.3 ng/mL
- 4.5 mg extended-releaseStudy 109, first dose to steady state6.4–7.7 ng/mL
- MINX 5 mg, fedAnagen two-person pilot; modeled peak, still rising at hour 86.5 ng/mL
In short: VDPHL01 has the larger evidence program and the regulatory path; MINX has availability now, a later modeled peak, and full public disclosure of its (much smaller) dataset. MINX is a 503A compounded formulation, available by prescription, and is not an FDA-approved drug. Talk to a physician before starting or changing any treatment, especially if you have any history of cardiovascular disease.
Frequently asked questions
VDPHL01, answered straight
Is VDPHL01 available now?
VDPHL01 is investigational and available only inside Veradermics’ clinical trials. It is not FDA approved, cannot be prescribed, and has no announced launch date; third-party projections place potential approval in late 2027 at the earliest if the remaining Phase 3 results and FDA review go the company’s way.
What blood levels does VDPHL01 produce?
Veradermics’ prospectus reports that in 24 healthy women, a 4.5 mg extended-release dose produced a geometric-mean peak of 6.417 ng/mL after the first dose and 7.735 ng/mL at steady state after a week of twice-daily dosing, against 135.1 ng/mL for 20 mg immediate-release minoxidil after a washout. In an exploratory dose-ranging study, 8.5 mg of extended-release prototype peaked at 8.32 ng/mL. The company has not published a numerical time-to-peak for the extended-release form.
Is VDPHL01 the same as low-dose oral minoxidil from a compounding pharmacy?
No. VDPHL01 is a proprietary extended-release formulation in clinical trials. Compounded oral minoxidil, including MINX, is prepared per prescription under section 503A and is not FDA approved. The active molecule is the same; the delivery, evidence base, and regulatory status differ.
What does the 30–360 minute figure mean?
The figure comes from the Veradermics patent family, which describes minoxidil formulations whose blood peak arrives between half an hour and six hours after dosing. Whether the commercial VDPHL01 formulation actually matches that description is not publicly known, because no measured time-to-peak has been published for it.
Is VDPHL01 the same drug as MINX?
Both deliver oral minoxidil slowly rather than all at once, and that is where the similarity ends. VDPHL01 is an investigational extended-release product in Phase 3 trials, built on a polymer-matrix approach per its patent family. MINX is a lipid-matrix formulation compounded per prescription under 503A, available now, with strong signs of extended-release behavior in early observational testing.
Is extended-release minoxidil better than regular oral minoxidil?
Plausibly, though no trial has compared them head-to-head. Immediate-release minoxidil produces a sharp plasma peak, and the peak is what drives its cardiovascular side effects: tachycardia and fluid retention. It also might be more effective: the follicle enzyme that switches minoxidil on, SULT1A1, has limited capacity, so drug that arrives faster than it can be converted adds exposure without adding effect.
How much will VDPHL01 cost?
Veradermics has not disclosed pricing.
Sources
Every claim, traced to its source
- 1Veradermics, Inc. Prospectus (Form S-1), February 2026.
- 2Veradermics, Inc. Form 8-K, Exhibit 99.1: Study 302 topline results, 27 April 2026.
- 3Dermatology Times Phase 2/3 Trial of Extended-Release Oral Minoxidil Shows Robust Hair Growth Outcomes in Male Pattern Hair Loss. https://www.dermatologytimes.com/view/phase-2-3-trial-of-extended-release-oral-minoxidil-shows-robust-hair-growth-outcomes-in-male-pattern-hair-loss
- 4Study 207, NCT06527365. https://clinicaltrials.gov/study/NCT06527365
- 5Study 302, NCT06724614. https://clinicaltrials.gov/study/NCT06724614
- 6Study 304, NCT06972264. https://clinicaltrials.gov/study/NCT06972264
- 7Study 306, NCT07146022. https://clinicaltrials.gov/study/NCT07146022
- 8Fleishaker JC, Andreadis NA, Welshman IR, Wright CE III The pharmacokinetics of 2.5- to 10-mg oral doses of minoxidil in healthy volunteers. PMID 2715373doi:10.1002/j.1552-4604.1989.tb03307.x
Available today
Smooth release minoxidil you can be prescribed now
MINX is smooth-release oral minoxidil designed for an extended-release profile. It demonstrated that profile in observational testing.
